These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 12949556)

  • 41. Could bank loans solve Europe's biotech financing slump?
    Mitchell P
    Nat Biotechnol; 2005 Dec; 23(12):1459-60. PubMed ID: 16333276
    [No Abstract]   [Full Text] [Related]  

  • 42. Biotechs for pennies?
    Jacobs T
    Nat Biotechnol; 2004 Dec; 22(12):1509. PubMed ID: 15583652
    [No Abstract]   [Full Text] [Related]  

  • 43. Paying over the odds.
    Jacobs T
    Nat Biotechnol; 2006 Jan; 24(1):29. PubMed ID: 16404388
    [No Abstract]   [Full Text] [Related]  

  • 44. Reverse mergers attract top-tier biotechs in sluggish IPO market.
    Lawrence S
    Nat Biotechnol; 2006 Jun; 24(6):598-9. PubMed ID: 16763574
    [No Abstract]   [Full Text] [Related]  

  • 45. When your stock takes a nosedive.
    Jacobs T
    Nat Biotechnol; 2006 Feb; 24(2):144. PubMed ID: 16465152
    [No Abstract]   [Full Text] [Related]  

  • 46. The protection racket.
    Jacobs T
    Nat Biotechnol; 2006 Sep; 24(9):1081. PubMed ID: 16964213
    [No Abstract]   [Full Text] [Related]  

  • 47. Investing in nanotechnology.
    Paull R; Wolfe J; Hébert P; Sinkula M
    Nat Biotechnol; 2003 Oct; 21(10):1144-7. PubMed ID: 14520393
    [No Abstract]   [Full Text] [Related]  

  • 48. Diversa restructures, raising question over bioprospecting.
    Sheridan C
    Nat Biotechnol; 2006 Mar; 24(3):229. PubMed ID: 16525364
    [No Abstract]   [Full Text] [Related]  

  • 49. US credit crunch impacts biotech across the globe.
    Mitchell P
    Nat Biotechnol; 2008 Apr; 26(4):359-60. PubMed ID: 18391997
    [No Abstract]   [Full Text] [Related]  

  • 50. 2006: a stellar year for financing.
    Lawrence S
    Nat Biotechnol; 2007 Feb; 25(2):156. PubMed ID: 17287738
    [No Abstract]   [Full Text] [Related]  

  • 51. A reprise for collaborative financing in biotech.
    Ransom J
    Nat Biotechnol; 2006 Aug; 24(8):873-4. PubMed ID: 16900110
    [No Abstract]   [Full Text] [Related]  

  • 52. Biotech holds its own in Q2.
    Lawrence S
    Nat Biotechnol; 2004 Aug; 22(8):938. PubMed ID: 15286634
    [No Abstract]   [Full Text] [Related]  

  • 53. White biotechnology: ready to partner and invest in.
    Kircher M
    Biotechnol J; 2006; 1(7-8):787-94. PubMed ID: 16897821
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Increasing number of companies found ineligible for SBIR funding.
    Bouchie A
    Nat Biotechnol; 2003 Oct; 21(10):1121-2. PubMed ID: 14520384
    [No Abstract]   [Full Text] [Related]  

  • 55. Whither agbiotechnology?
    Val Giddings L
    Nat Biotechnol; 2006 Mar; 24(3):274-6. PubMed ID: 16525385
    [No Abstract]   [Full Text] [Related]  

  • 56. Eli Lilly enters venture capital arena.
    Fletcher L
    Nat Biotechnol; 2001 Nov; 19(11):997-8. PubMed ID: 11689830
    [No Abstract]   [Full Text] [Related]  

  • 57. This means war.
    Nat Biotechnol; 2008 Sep; 26(9):954. PubMed ID: 18779784
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Another clue to biotech value.
    Jacobs T
    Nat Biotechnol; 2003 Jul; 21(7):746. PubMed ID: 12833091
    [No Abstract]   [Full Text] [Related]  

  • 59. Companies struggle amid stock market gloom.
    Mitchell P
    Nat Biotechnol; 2002 Oct; 20(10):961-2. PubMed ID: 12355102
    [No Abstract]   [Full Text] [Related]  

  • 60. The importance of angels in starting a US biotech venture.
    Sohl J
    Nat Biotechnol; 2005 Feb; 23(2):263-4. PubMed ID: 15724275
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.